Thus, our study reveals that the chemotherapy-induced increase in pyrimidine salvage pathway expression, e.g., increased CDA and TYMP, might be exploited in the clinical setting to target therapy-resistant lung cancer by schedule-dependent treatment with Capecitabine. Here, CDA is linked to lung carcinoma.